VESALIUS– Vesalius is a clinical trial evaluating if treatment with additional cholesterol lowering medication reduces the risk of major cardiovascular events in patients at high cardiovascular risk
To be eligible to participate you must be:
- Between 50-80 years (men) or 55-80 years (women) of age
- LDL-Cholesterol ≥ 3 mmol/L or non-HDL ≥ 3.1 mmol/L after ≥ 2 weeks of optimised lipid lowering therapy
- Evidence of either significant coronary artery disease, atherosclerotic cerebrovascular disease, peripheral arterial disease or diabetes mellitus
- Have at least one high risk feature of family history of premature coronary artery disease, familial hypercholesterolaemia, current smoker, 65 years of age or menopause before 40 years of age.
Participation is for 4 years and involves being screened in a clinic on Day 1, and then return to the clinic every 4 months for drug dispensation. During these visits you will be asked about your health and medications. You will be reimbursed for your travel.
For further information, or to register your interest telephone 1800 770 664 or email email@example.com
Curtin University Human Research Ethics Committee (HREC) has approved this study (HREC number 2021-0049)
Copyright © CCRE. All Rights Reserved
Centre of Clinical Research and Education
Address: School of Population Health, Curtin University, Bentley WA 6102